Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Halozyme ( (HALO) ) just unveiled an update.
On October 1, 2025, Halozyme Therapeutics appointed Cortney Caudill as Senior Vice President, Chief Operating Officer. Ms. Caudill, who joined Halozyme in October 2023, brings extensive experience from her previous roles at Aeglea Biotherapeutics and other life sciences companies. Her appointment is expected to bolster Halozyme’s operational capabilities, with her compensation package including a $600,000 base salary and equity awards, aligning her incentives with the company’s long-term growth objectives.
The most recent analyst rating on (HALO) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.
Spark’s Take on HALO Stock
According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.
Halozyme’s strong financial performance and positive earnings call sentiment are the primary drivers of its high score. The technical analysis indicates strong momentum, although caution is advised due to overbought signals. The valuation is reasonable, supporting the overall positive outlook.
To see Spark’s full report on HALO stock, click here.
More about Halozyme
Halozyme Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing innovative therapies that target the extracellular matrix for the treatment of cancer and other diseases.
Average Trading Volume: 1,950,434
Technical Sentiment Signal: Buy
Current Market Cap: $8.07B
For a thorough assessment of HALO stock, go to TipRanks’ Stock Analysis page.